drugset / Trial / NCT00790244

A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall

NCT00790244 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

SSG XX is a phase II trial for high-risk soft tissue sarcomas (STS) of the extremities and trunk wall. Prognostic factors (histopathological markers) are used to identify high-risk tumors. SSG XX will evaluate chemo- and radiotherapy given adjuvantly to these patients. In a specified group of patients also preoperatively given therapy will be studied.

Timeline

Start
2007-10
Primary completion
2012-10
Completion
2022-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 50 mg/m2 —
Subject Doxorubicin Other / unclassified 60 mg/m2 —
Subject Ifosfamide Small molecule 5 g —
Subject Ifosfamide Small molecule 6 g —

Indications